{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:21:44Z","timestamp":1787235704958,"version":"build-2736575974"},"reference-count":34,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T00:00:00Z","timestamp":1749168000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p>Background\/Objectives: Patients with inflammatory bowel disease (IBD) are at an increased risk of various cancers; such as colorectal cancer; skin cancer; bile duct cancer; or lymphoma; with IBD itself not being the sole cause. Inappropriate or ineffective IBD therapy with a continuous inflammatory burden within the gut leads to an increased risk of malignancy. Our study aimed to investigate the risk of malignancy in our patient cohort; focusing on concomitant therapy; disease duration; and inflammatory burden. Methods: A total of 333 consecutive adult patients with IBD (Crohn\u2019s disease; ulcerative colitis; and IBD unclassified) were included in this study. Data from patients were collected retrospectively using patient charts. The patients were treated in the gastroenterological outpatient clinic of the University Hospital of Augsburg; Germany; between 1 January 2014 and 31 December 2018. Results: The study group included 333 patients; 32 (9.61%) of whom suffered from malignancy (any form). Men (n = 21; 65.62%) tended to develop malignancy more often than women (n = 11; 34.38%, p = 0.051). It was also observed that the probability of developing cancer was 2.40 times higher in male patients than in female patients in our cohort. However, this trend was non-significant (HR = 2.412; p = 0.075). Furthermore; the probability of developing cancer increased with the increasing age at the time of the first diagnosis of IBD (HR = 1.088; p &lt; 0.025). A total of 20 patients (6.00%) received their cancer diagnosis after being diagnosed with IBD. The majority of those patients had skin (n = 6; 30.00%) or colon cancer (n = 5; 25.00%). Other diseases such as CML; NHL; HL; HCC; liver sarcoma; prostate cancer; breast cancer; seminoma; thyroid cancer (a second cancer in one of the patients); or CUP syndrome\/lung cancer were diagnosed in single patients. Patients with IBD and colon cancer (n = 5; 25.00%) shared some of the known risk factors for tumour development; such as a long-lasting IBD (n = 5; 100.00%), diagnosis at a young age (under 30; n = 3; 60.00%), and the coexistence of PSC (n = 1; 20.00%). The cancer prevalence rate was relatively low in our cohort despite the use of diverse biologics and immunosuppressive drugs. Faecal calprotectin was confirmed as a relevant tool for inflammation monitoring in this cohort. Conclusions: In our study cohort; we could show a low prevalence rate of malignancy in IBD. There were more malignancies in men and in patients who were diagnosed with IBD at later ages. It can be observed that the prevalence rate of cancer was relatively low despite the use of diverse biologics and immunosuppressive drugs; which is the major conclusion of this study. Additionally; the known correlation between elevated levels of faecal calprotectin and gut inflammation was confirmed through our statistical analysis. The use of calprotectin as a non-invasive screening tool for gut inflammation is advised.<\/jats:p>","DOI":"10.3390\/biomedicines13061395","type":"journal-article","created":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T06:11:08Z","timestamp":1749190268000},"page":"1395","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Malignancy and Inflammatory Bowel Disease (IBD): Incidence and Prevalence of Malignancy in Correlation to IBD Therapy and Disease Activity\u2014A Retrospective Cohort Analysis over 5 Years"],"prefix":"10.3390","volume":"13","author":[{"given":"Agnieszka Jowita","family":"Kafel","sequence":"first","affiliation":[{"name":"Internal Medicine III, University Hospital Augsburg, 86156 Augsburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4441-8006","authenticated-orcid":false,"given":"Anna","family":"Muzalyova","sequence":"additional","affiliation":[{"name":"Internal Medicine III, University Hospital Augsburg, 86156 Augsburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Schnoy","sequence":"additional","affiliation":[{"name":"Internal Medicine III, University Hospital Augsburg, 86156 Augsburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,6,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"113","DOI":"10.25122\/jml-2018-0075","article-title":"A review of the diagnosis, prevention, and treatment methods of inflammatory bowel disease","volume":"12","author":"Seyedian","year":"2019","journal-title":"J. Med. Life"},{"key":"ref_2","first-page":"j3951","article-title":"Childhood onset inflammatory bowel disease and risk of cancer: A Swedish nationwide cohort study 1964\u20132014","volume":"358","author":"Askling","year":"2017","journal-title":"BMJ"},{"key":"ref_3","first-page":"72","article-title":"Inflammatory Bowel Disease","volume":"113","author":"Wehkamp","year":"2016","journal-title":"Dtsch. Arztebl. Int."},{"key":"ref_4","unstructured":"Medycyna, P. (2014). Interna Szczeklika: Podr\u0119cznik Chor\u00f3b Wewn\u0119trznych, Medycyna Praktyczna."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Messmann, H., Andus, T., and Baum, K. (2012). Klinische Gastroenterologie: Das Buch F\u00fcr Fort-Und Weiterbildung, Thieme. plus DVD mit \u00fcber 1400 Befunden; 312 Tabellen; inklusive DVD.","DOI":"10.1055\/b-002-29655"},{"key":"ref_6","first-page":"3","article-title":"What is the Impact of Age on Adult Patients with Inflammatory Bowel Disease?","volume":"86","author":"Prelipcean","year":"2013","journal-title":"Clujul Med."},{"key":"ref_7","first-page":"12","article-title":"Chronisch-Entz\u00fcndliche Darmerkrankungen","volume":"70","year":"2016","journal-title":"Hambg. \u00c4rzteblatt"},{"key":"ref_8","unstructured":"Peppercorn, M.A., and Cheifetz, A.S. (2025, May 13). Definitions, Epidemiology, and Risk Factors for Inflammatory Bowel Disease in Adults. Available online: https:\/\/www.uptodate.com\/contents\/definitions-epidemiology-and-risk-factors-for-inflammatory-bowel-disease."},{"key":"ref_9","unstructured":"Friedman, G., and Bitton, A. (2024, July 08). Overview of Hepatobiliary Disorders in Patients with Inflammatory Bowel Disease. Available online: https:\/\/www.uptodate.com\/contents\/overview-of-hepatobiliary-disorders-in-patients-with-inflammatory-bowel-disease."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"S082","DOI":"10.1093\/ecco-jcc\/jjz203.082","article-title":"The risk of extra-intestinal cancer in inflammatory bowel disease (IBD): A systematic review and meta-analysis of population-based cohort studies","volume":"14","author":"Lo","year":"2020","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.3748\/wjg.14.2662","article-title":"Colorectal cancer and dysplasia in inflammatory bowel disease","volume":"14","author":"Zisman","year":"2008","journal-title":"World J. Gastroenterol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"S496","DOI":"10.1093\/ecco-jcc\/jjz203.724","article-title":"Risk of colorectal cancer and other malignancies in association with the use of thiopurines, tumour necrosis factor antagonists or mesalazine","volume":"14","author":"Timeus","year":"2020","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1093\/ecco-jcc\/jjaa089","article-title":"Incidence, Risk Factors and Outcomes of Cancer of the Anal Transitional Zone in Patients with Ulcerative Colitis","volume":"14","author":"Horio","year":"2020","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1093\/ecco-jcc\/jjy006","article-title":"Reduced Risk of Inflammatory Bowel Disease-associated Colorectal Neoplasia with Use of Thiopurines: A Systematic Review and Metaanalysis","volume":"12","author":"Zhu","year":"2018","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"9872","DOI":"10.3748\/wjg.v20.i29.9872","article-title":"Colorectal cancer in inflammatory bowel disease: The risk, pathogenesis, prevention and diagnosis","volume":"20","author":"Kim","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1053\/j.gastro.2013.03.044","article-title":"Risk of colorectal high-grade dysplasia and cancer in a prospective observational cohort of patients with inflammatory bowel disease","volume":"145","author":"Beaugerie","year":"2013","journal-title":"Gastroenterology"},{"key":"ref_17","first-page":"e241","article-title":"Aktualisierte S3-Leitlinie Colitis ulcerosa\u2014Living Guideline","volume":"58","author":"Kucharzik","year":"2020","journal-title":"Z. F\u00fcr Gastroenterologie"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3839","DOI":"10.3748\/wjg.v18.i29.3839","article-title":"Colorectal cancer in inflammatory bowel disease: What is the real magnitude of the risk?","volume":"18","author":"Dyson","year":"2012","journal-title":"World J Gastroenterol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/0016-5085(94)90068-X","article-title":"Risk factors for colorectal cancer in patients with ulcerative colitis: A case-control study","volume":"107","author":"Pinczowski","year":"1994","journal-title":"Gastroenterology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1002\/cncr.34390","article-title":"Sex disparities in the incidence of 21 cancer types: Quantification of the contribution of risk factors","volume":"128","author":"Jackson","year":"2022","journal-title":"Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1093\/ecco-jcc\/jjx040","article-title":"Cancer Risk in the Early Stages of Inflammatory Bowel Disease in Korean Patients: A Nationwide Population-based Study","volume":"11","author":"Jung","year":"2017","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1093\/ecco-jcc\/jjv141","article-title":"European Evidence-based Consensus: Inflammatory Bowel Disease and Malignancies","volume":"9","author":"Annese","year":"2015","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"S007","DOI":"10.1093\/ecco-jcc\/jjz203.007","article-title":"Inflammatory bowel disease and risk of small bowel cancer: A binational population-based cohort study from Denmark and Sweden","volume":"14","author":"Axelrad","year":"2020","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1093\/ecco-jcc\/jjz157","article-title":"Small Bowel Adenocarcinoma: Is There a Difference in Survival for Crohn\u2019s Versus Sporadic Cases?","volume":"14","author":"Fields","year":"2020","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_25","first-page":"2","article-title":"Begleiterkrankungen bei CED Onkologische Fragen CED und Krebserkrankungen","volume":"1","author":"Kannengiesser","year":"2018","journal-title":"Bauchredner"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1055\/s-0034-1385199","article-title":"Aktualisierte S3-Leitlinie\u2014\u201dDiagnostik und Therapie des Morbus Crohn\u201d 2014","volume":"52","author":"Bokemeyer","year":"2014","journal-title":"Z. F\u00fcr Gastroenterol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"S453","DOI":"10.1093\/ecco-jcc\/jjz203.655","article-title":"A review of adverse events associated with immunosuppressive treatments in inflammatory bowel disease patients","volume":"14","author":"Tassone","year":"2020","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_28","unstructured":"A-Rahim, Y.I., and Farrell, R.J. (2024, April 19). Overview of Azathioprine and Mercaptopurine Use in Inflammatory Bowel Disease. Available online: http:\/\/112.2.34.14:9095\/contents\/overview-of-azathioprine-and-mercaptopurine-use-in-inflammatory-bowel-disease."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1093\/ecco-jcc\/jjaa186","article-title":"TNF inhibitors and risk of malignancy in patients with inflammatory bowel diseases: A systematic review","volume":"15","author":"Muller","year":"2020","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_30","unstructured":"Hashash, J.A., and Regueito, M. (2025, May 22). Medical Management of Low-Risk Adult Patients with Mild to Moderate Ulcerative Colitis. Available online: https:\/\/www.uptodate.com\/contents\/medical-management-of-low-risk-adult-patients-with-mild-to-moderate-ulcerative-colitis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1055\/a-1713-3941","article-title":"Aktualisierte S3-Leitlinie \u201cDiagnostik und Therapie des Morbus Crohn\u201d der Deutschen Gesellschaft f\u00fcr Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS)-August 2021-AWMF-Registernummer: 021-004","volume":"60","author":"Sturm","year":"2022","journal-title":"Z. F\u00fcr Gastroenterol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF Antibody Therapy in rheumatoid arthritis and the risk of serious infections and malignancies: Systematic Review and Meta-analysis of rare harmful effects in randomized controlled trials","volume":"295","author":"Bongartz","year":"2006","journal-title":"JAMA"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1053\/j.gastro.2017.02.004","article-title":"Infliximab Is Not Associated With Increased Risk of Malignancy or Hemophagocytic Lymphohistiocytosis in Pediatric Patients With Inflammatory Bowel Disease","volume":"152","author":"Hyams","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_34","first-page":"564","article-title":"Colitis ulcerosa\u2014Diagnostische und therapeutische Algorithmen","volume":"117","author":"Kucharzik","year":"2020","journal-title":"Dtsch. Aerzteblatt Online"}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/13\/6\/1395\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:47:30Z","timestamp":1760032050000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/13\/6\/1395"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,6]]},"references-count":34,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["biomedicines13061395"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines13061395","relation":{},"ISSN":["2227-9059"],"issn-type":[{"value":"2227-9059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,6]]}}}